View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 27, 2021updated 07 Jan 2022 8:57am

Roche’s COVID-19 At-Home Test obtains EUA from FDA

The test detects nucleocapsid protein of SARS-CoV-2 and provides results in 20 minutes for all Covid-19 variants, including Omicron.

The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) to Roche’s COVID-19 At-Home Test.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

A rapid chromatographic immunoassay, the Covid-19 test is designed to detect nucleocapsid protein of SARS-CoV-2.

Using anterior nasal swab samples, the test provides accurate results in 20 minutes for SARS-CoV-2 as well as all known Covid-19 variants, including the latest Omicron.

The samples can be self-collected and tested by individuals aged 14 years and above, and by adults for children aged between two and 13 years.

The company stated that in prospective clinical study, the at-home test kit demonstrated 100% relative specificity and 95.3% relative sensitivity.

The EUA has been granted through the company’s participation in Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program (ITAP) of the National Institutes of Health (NIH). Through this programme, NIH aims to bring rapid tests to the over the counter (OTC) market.

Roche Diagnostics CEO Thomas Schinecker said: “The Covid-19 pandemic continues to shed light on the critically important role that rapid self-testing plays in empowering individuals to protect their personal health and the health of their families and communities.

“At this inflection point in the American public’s fight against Covid-19, we are proud to have worked in close collaboration with the US Government to introduce and expand access to accurate, reliable and high-quality at-home tests.”

The new at-home test will become available for purchase at pharmacies and retailers across the US from January 2022.

The company has a global distribution agreement with SD Biosensor, which has also been previously involved in the launch of a range of Covid-19 tests.

Roche claimed that it has capability to produce ‘tens of millions’ of its Covid-19at-home tests per month at the time of launch in the US.

Roche also intends to provide NAVIFY Pass to organisations along with its COVID-19 At-Home Test to enable people to store, display, and share the test results remotely.

Recently, the company obtained CE mark for the use of saliva samples with its cobas SARS-CoV-2 Qualitative test to detect SARS-CoV-2.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network